Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
29 hedge funds and large institutions have $7.26M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
4% more funds holding
Funds holding: 28 → 29 (+1)
2% more capital invested
Capital invested by funds: $7.09M → $7.26M (+$168K)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$356K |
| 2 |
Renaissance Technologies
New York
|
+$164K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$99.4K |
| 4 |
PCM
Perritt Capital Management
Chicago,
Illinois
|
+$19.7K |
| 5 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
+$15.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$203K |
| 2 |
Squarepoint
New York
|
-$90K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$63.7K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$26.9K |
| 5 |
Morgan Stanley
New York
|
-$17.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ASN
26
Advisory Services Network
Atlanta,
Georgia
| $3K | +$2.75K | +350 | New |
|
|
ARMC
27
American Research & Management Company
Marion,
Massachusetts
| $2K | – | – | – |
|
28
Fidelity Investments
Boston,
Massachusetts
| $2K | – | – | – |
|
29
Federated Hermes
Pittsburgh,
Pennsylvania
| $2K | +$441 | +56 | +23% |
|
|
GCP
30
GSA Capital Partners
London,
United Kingdom
| – | -$203K | -27,110 | Closed |
|
|
31
Squarepoint
New York
| – | -$90K | -12,087 | Closed |
|
|
PCM
32
Prelude Capital Management
New York
| – | -$10K | -1,400 | Closed |
|
OPNT Hedge Fund Activity: Q4 2020 in Review
29 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q4 2020, worth a combined $7.26M — up 2.4% from $7.09M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new OPNT positions and 3 closed out — a net gain of 2 holders — while 7 added to existing stakes and 7 trimmed.
The largest buyer was Wells Fargo, adding an estimated $356K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $203K sold.
- 29 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q4 2020, up from 28 in Q3 2020.
- Funds reported $7.26M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q4 2020, up 2.4% quarter-over-quarter.
- 5 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q4 2020 and 3 closed out, a net change of +2 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q4 2020 was Wells Fargo, an estimated $356K added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q4 2020 was GSA Capital Partners, an estimated $203K sold.
Based on aggregated 13F filings for Q4 2020.